Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000706795 | SCV000835865 | pathogenic | Familial adenomatous polyposis 2 | 2023-07-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 582666). This variant has not been reported in the literature in individuals affected with MUTYH-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu60*) in the MUTYH gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MUTYH are known to be pathogenic (PMID: 18534194, 20663686). |
Ambry Genetics | RCV004026730 | SCV005038210 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-02-23 | criteria provided, single submitter | clinical testing | The p.E60* variant (also known as c.178G>T), located in coding exon 3 of the MUTYH gene, results from a G to T substitution at nucleotide position 178. This changes the amino acid from a glutamic acid to a stop codon within coding exon 3. This region of the MUTYH gene is excluded from other biologically relevant MUTYH transcripts. Based on the available evidence, the clinical significance of this alteration remains unclear. |